Avant Diagnostics (OTCMKTS:AVDX) and Fly Leasing (NYSE:FLY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Avant Diagnostics and Fly Leasing, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avant Diagnostics 0 0 0 0 N/A
Fly Leasing 2 0 1 0 1.67

Fly Leasing has a consensus price target of $19.83, indicating a potential upside of 57.16%. Given Fly Leasing’s higher possible upside, analysts clearly believe Fly Leasing is more favorable than Avant Diagnostics.

Institutional & Insider Ownership

0.0% of Avant Diagnostics shares are held by institutional investors. Comparatively, 49.5% of Fly Leasing shares are held by institutional investors. 38.0% of Avant Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares Avant Diagnostics and Fly Leasing’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avant Diagnostics N/A N/A N/A
Fly Leasing 15.32% 11.41% 1.80%

Risk & Volatility

Avant Diagnostics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, Fly Leasing has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.

Valuation and Earnings

This table compares Avant Diagnostics and Fly Leasing’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avant Diagnostics $110,000.00 61.27 -$11.75 million N/A N/A
Fly Leasing $353.25 million 1.02 $2.59 million $0.09 140.11

Fly Leasing has higher revenue and earnings than Avant Diagnostics.


Fly Leasing beats Avant Diagnostics on 8 of the 11 factors compared between the two stocks.

Avant Diagnostics Company Profile

Avant Diagnostics, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic tests that provide information for physicians and patients in the areas of cancers. It offers OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer; and MSPrecise, a DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. The company is based in Washington, District of Columbia.

Fly Leasing Company Profile

Fly Leasing Limited, through its subsidiaries, purchases and leases commercial aircrafts under multi-year contracts to various airlines worldwide. As of December 31, 2017, the company had a portfolio of 85 aircrafts, including 73 narrow-body passenger aircrafts and 12 wide-body passenger aircrafts. Fly Leasing Limited was founded in 2007 and is headquartered in DĂșn Laoghaire, Ireland.

Receive News & Ratings for Avant Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avant Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.